Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vancomycin solution Clear all
Terminated Phase 2Phase 3 Interventional Results available

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03105479
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin capsule, Vancomycin solution
Drug
Lead sponsor
Actelion
Industry
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)

NCT01579370
View directory record Official record
Conditions
Multidrug Resistant Organisms, Healthcare Associated Infections
Interventions
Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light, Bleach and UV-C light
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Early Phase 1 Interventional

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643
View directory record Official record
Conditions
Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions
vancomycin or gentamicin, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 21, 2026, 10:34 AM EDT
Not listed Early Phase 1 Interventional

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

NCT05076955
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
vancomycin-tobramycin-itraconazole
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 21, 2026, 10:34 AM EDT
Withdrawn Phase 4 Interventional

Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI

NCT04241744
View directory record Official record
Conditions
CDI
Interventions
Vancomycin 125 MG po BID
Drug
Lead sponsor
Creighton University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 10:34 AM EDT
Recruiting Phase 2Phase 3 Interventional

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

NCT07221370
View directory record Official record
Conditions
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Interventions
Vancomycin 125mg, Placebo
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 10:34 AM EDT
Not listed Phase 3 Interventional

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT02901717
View directory record Official record
Conditions
Catheter-related Infections
Interventions
Mino-Lok, Antibiotic lock
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Hines, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 21, 2026, 10:34 AM EDT
Not yet recruiting Not applicable Interventional

Intraosseous Antibiotics for Osseointegration

NCT07621094
View directory record Official record
Conditions
Osseointegration Infection
Interventions
intraosseous antibiotic delivery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Results available

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

NCT04075526
View directory record Official record
Conditions
Osteoarthritis
Interventions
Povidone iodine, Vancomycin powder, Conventional
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
2,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Rancho Mirage, California • Denver, Colorado • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 21, 2026, 10:34 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?

NCT03713528
View directory record Official record
Conditions
Joint Infection
Interventions
Intraoperative Intraosseous Vancomycin
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Weston, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 10:34 AM EDT
Suspended Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

NCT05715619
View directory record Official record
Conditions
Vancomycin-Resistant Enterococcal Colonization
Interventions
VRELysin™, Placebo
Biological · Other
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 21, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 21, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

Preoperative Antibiotics for Carpal Tunnel Release Surgery

NCT03432858
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Vancomycin, Cefazolin, Saline Solution
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Topical Vancomycin for Neurosurgery Wound Prophylaxis

NCT02284126
View directory record Official record
Conditions
Infection, Surgery, Nervous System Diseases
Interventions
Vancomycin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Prevention of Neurosurgical Wound Infections

NCT00915967
View directory record Official record
Conditions
Surgical Wound Infections
Interventions
Vancomycin, Placebo (Saline Solution)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 10:34 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Fecal Transplant for Relapsing C. Difficile Infection

NCT01703494
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation, Sham Fecal Microbiota Transplantation
Biological
Lead sponsor
Colleen Kelly
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
The Bronx, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 21, 2026, 10:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement

NCT03506347
View directory record Official record
Conditions
Arthropathy of Knee Joint
Interventions
Vancomycin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 21, 2026, 10:34 AM EDT